Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT04814693

Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis

In acute pancreatitis, approximately 20% of the cases result in severe necrotizing pancreatitis which is associated with significant morbidity and mortality. Necrotizing pancreatitis is characterized by the development of an acute necrotic collection and as this collection persists beyond 4 weeks, walled off necrosis (WON) encapsulates the collection. To date, this is treated by the step-up approach, which contains percutaneous drainage and minimally invasive video assisted retroperitoneal debridement (VARD) or endoscopic ultrasound (EUS) guided drainage followed by direct endoscopic necrosectomy (DEN). Different DEN techniques are available for the treatment of WON, however, there is a lack of effective endoscopic instruments to perform DEN. Recently, the first dedicated alternative to conventional DEN has been cleared for use, namely the EndoRotor® Resection System. This device is a powered mechanical debridement device intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. Previous (pilot and feasibility) studies showed promising results in terms of the amount of procedures, adverse events and length of hospital stay.

Therefore, aim of this study is to assess the performance of the EndoRotor, as compared to conventional endoscopic techniques, for direct endoscopic necrosectomy (DEN) of walled off necrosis (WON) in a randomized controlled trial.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Acute Pancreatitis Communicable Diseases Digestive System Diseases Disease Attributes Infections Necrosis Necrosis; Pancreas, Acute (Infectious) Pancreatic Diseases Pancreatitis Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Copenhagen University Hospital, Hvidovre, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with symptomatic pancreatic necrosis due to acute pancreatitis that have an indication to undergo endoscopic necrosectomy after having undergone EUS-guided drainage.

a. Stent must be in place for a minimum of 2 days prior to the DEN procedure.

  • Patients who can tolerate repeat endoscopic procedures.
  • Subjects with the ability to understand the requirements of the study, who have provided written informed consent, and who are willing and able to return for the required follow-up assessments.
  • ASA classification < 5.

Exclusion criteria

  • Documented pseudoaneurysm > 1 cm within the WON.
  • Subject unable or unwilling to provide informed consent.
  • Intervening gastric varices or unavoidable blood vessels within the WON access tract (visible using endoscopy or endoscopic ultrasound).
  • Coagulation disorders or anti-coagulant therapy which cannot be discontinued (aspirin allowed).
  • Any condition that in the opinion of the Investigator would create an unsafe clinical situation or stent placement that would not allow the patient to safely undergo an endoscopic procedure.
  • Pregnant or lactating women or women of childbearing potential who do not employ a reliable method of contraception as judged by the Investigator, and/or are not willing to use reliable contraception for the duration of study participation.
  • Patient is enrolled in another trial that could interfere with the endpoint analyses of this trial.
  • Prior necrosectomy on existing collection.
  • Greater than 2 pancreatic / extra-pancreatic fluid collections.

Treatment and study plan

EndoRotor® System (Interscope, Inc., Northbridge, MA USA),

Device

The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.

Conventional endoscopic devices (according to standards of care)

Procedure

Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.

Primary outcomes

  1. The number of DEN procedures required to achieve resolution of WON

    Time frame: During a 6 month follow up period

    • Resolution is defined as clinical improvement of WON symptoms precluding the need for additional endoscopic or surgical interventions.
    • Clinical improvement is defined according to the criteria used in the PANTER trial and TENSION trial.8,15 "Clinical improvement" was defined as:

    i. Improved function of at least two organ systems (i.e. circulatory, pulmonary, renal) according to the Investigator's medical judgement within 72 hours, or; ii. At least 10% improvement of two out of three parameters of infection (i.e. C-reactive protein, leucocyte count or temperature) within 72 hours.

Secondary outcomes

  1. Adverse events

    Time frame: During a 6 month follow up period

    The occurrence of all adverse events measured from the Index Procedure through the 6 Month Post Necrosectomy Follow-up Visit

  2. Conversion to surgery defined as number of subject that require surgical intervention as a result of DEN failure as assessed by the Investigator during the index procedure through the 6 month post necrosectomy follow-up visit

    Time frame: During a 6 month follow up period

    In case of conversion to surgery, reason for conversion and type of surgical procedure

  3. Length of hospitalization

    Time frame: During a 6 month follow up period

    Length of hospitalization measured in days from the Index Procedure, including days in intensive care unit (ICU) vs. standard in-patient hospitalization

  4. Mean total cost of care per subject

    Time frame: During a 6 month follow up period

    Mean total cost of care per subject including: procedure costs, debridement devices used during the procedure, and inpatient hospital stay from the date of procedure to the date of discharge based on reimbursement fee structure expressed in US dollars, Euros or UK Pounds respectively.

    a. Procedure costs will be based on the cost of an endoscopic retrograde cholangiopancreatography (ERCP) which covers room, X-ray, sedation, personnel, and other materials.

  5. Percent reduction in WON collection volume (cm3)

    Time frame: During a 6 month follow up period

    Assessed by contrast enhanced computed tomography (CECT) scan or magnetic resonance imaging (MRI) (Baseline vs. completion of necrosectomy). Percent reduction in WON collection volume (cm3) as assessed by contrast enhanced computed tomography (CECT) scan or magnetic resonance imaging (MRI) (Baseline vs. completion of necrosectomy).

    • Endoscopic ultrasound (EUS) may be used for imaging only when a subject is contraindicated for MRI and CECT.
    • WON collection volume will be measured as follows:

    i. Length = longest diameter in cm/mm in the axial plane (left - right) ii. Width = the longest diameter in cm/mm (frontal - dorsal) in the same axial plane as the length, perpendicular on the longitudinal axis.

    iii. Height = longest diameter in cm/mm on coronal plane (cranial - caudal)

  6. Procedure time

    Time frame: During a 6 month follow up period

    Measured in minutes from the point of per-oral scope insertion to scope removal (scope-in / scope-out).

  7. Debridement time

    Time frame: During a 6 month follow up period

    Measured in minutes from the start of the debridement procedure to completion of the debridement procedure, including time to swap devices.

  8. Subject Quality of Life

    Time frame: During a 6 month follow up period

    Subject quality of life (QOL) as assessed by a SF-36 questionnaire performed at Baseline, Discharge, and at the 1, 3, and 6 Month Post Necrosectomy Follow-up Visits.

  9. The number of device deficiencies, defined as any inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performance including malfunction, use errors, and inadequate labelingprocedure

    Time frame: During a 6 month follow up period

    Assessed by the Investigator during each DEN procedure. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Collaborators

  • Interscope, Inc.

Registry information

Official study title

A Prospective, Post-Market, Multicenter, Randomized Controlled Trial to Compare the Performance of the EndoRotor® System Versus Conventional Endoscopic Techniques for Direct Endoscopic Necrosectomy of Walled Off Necrosis - The RESOlVE Trial

Acronym: RESOlVE

Important dates

Study start
2022
Primary completion
2026
Study completion
2027
First posted
Mar 24, 2021
Registry last updated
Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.